Ken Griffin’s AC Immune ACIU Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $735K | Buy |
267,233
+196,082
| +276% | +$609K | ﹤0.01% | 8401 |
|
|
2025
Q4 | $223K | Buy |
71,151
+51,038
| +254% | +$161K | ﹤0.01% | 10795 |
|
|
2025
Q3 | $58.1K | Sell |
20,113
-125,886
| -86% | -$284K | ﹤0.01% | 12120 |
|
|
2025
Q2 | $296K | Sell |
145,999
-5,462
| -4% | -$9.5K | ﹤0.01% | 9856 |
|
|
2025
Q1 | $283K | Buy |
151,461
+143,598
| +1,826% | +$362K | ﹤0.01% | 9731 |
|
|
2024
Q4 | $21.2K | Sell |
7,863
-13,943
| -64% | -$43.6K | ﹤0.01% | 13142 |
|
|
2024
Q3 | $82.4K | Sell |
21,806
-13,002
| -37% | -$45.4K | ﹤0.01% | 11378 |
|
|
2024
Q2 | $139K | Sell |
34,808
-25,924
| -43% | -$85.8K | ﹤0.01% | 10458 |
|
|
2024
Q1 | $180K | Buy |
+60,732
| New | +$218K | ﹤0.01% | 10491 |
|
|
2023
Q4 | – | Sell |
-1,097
| Closed | -$3.53K | – | 14170 |
|
|
2023
Q3 | $3.13K | Buy |
+1,097
| New | +$3.34K | ﹤0.01% | 13629 |
|
|
2023
Q2 | – | Sell |
-3,165
| Closed | -$6.91K | – | 14253 |
|
|
2023
Q1 | $7.41K | Sell |
3,165
-163,898
| -98% | -$379K | ﹤0.01% | 13726 |
|
|
2022
Q4 | $341K | Buy |
+167,063
| New | +$431K | ﹤0.01% | 9039 |
|
|
2022
Q1 | – | Sell |
-25,613
| Closed | -$111K | – | 13458 |
|
|
2021
Q4 | $127K | Sell |
25,613
-10,427
| -29% | -$60.6K | ﹤0.01% | 12465 |
|
|
2021
Q3 | $242K | Buy |
36,040
+14,273
| +66% | +$102K | ﹤0.01% | 11543 |
|
|
2021
Q2 | $172K | Sell |
21,767
-15,027
| -41% | -$104K | ﹤0.01% | 12344 |
|
|
2021
Q1 | $280K | Buy |
+36,794
| New | +$263K | ﹤0.01% | 11012 |
|
|
2020
Q4 | – | Sell |
-23,970
| Closed | -$122K | – | 10848 |
|
|
2020
Q3 | $117K | Buy |
+23,970
| New | +$172K | ﹤0.01% | 9174 |
|
|
2020
Q2 | – | Sell |
-42,946
| Closed | -$297K | – | 9692 |
|
|
2020
Q1 | $297K | Sell |
42,946
-39,222
| -48% | -$307K | ﹤0.01% | 7353 |
|
|
2019
Q4 | $700K | Sell |
82,168
-38,169
| -32% | -$254K | ﹤0.01% | 6238 |
|
|
2019
Q3 | $595K | Sell |
120,337
-46,090
| -28% | -$247K | ﹤0.01% | 6468 |
|
|
2019
Q2 | $924K | Buy |
166,427
+42,414
| +34% | +$216K | ﹤0.01% | 5813 |
|
|
2019
Q1 | $626K | Sell |
124,013
-325,525
| -72% | -$2.07M | ﹤0.01% | 6398 |
|
|
2018
Q4 | $4.25M | Buy |
449,538
+164,701
| +58% | +$1.56M | ﹤0.01% | 3015 |
|
|
2018
Q3 | $2.28M | Buy |
+284,837
| New | +$2.86M | ﹤0.01% | 4194 |
|
|
2018
Q2 | – | Sell |
-15,743
| Closed | -$163K | – | 8749 |
|
|
2018
Q1 | $163K | Sell |
15,743
-61,849
| -80% | -$752K | ﹤0.01% | 7489 |
|
|
2017
Q4 | $993K | Hold |
77,592
| – | – | ﹤0.01% | 4664 |
|
|
2017
Q3 | $877K | Sell |
77,592
-63,101
| -45% | -$540K | ﹤0.01% | 4499 |
|
|
2017
Q2 | $1.24M | Sell |
140,693
-35,112
| -20% | -$325K | ﹤0.01% | 3793 |
|
|
2017
Q1 | $1.82M | Sell |
175,805
-197,668
| -53% | -$2.43M | ﹤0.01% | 3170 |
|
|
2016
Q4 | $4.85M | Buy |
373,473
+298,615
| +399% | +$4.13M | ﹤0.01% | 2034 |
|
|
2016
Q3 | $1.23M | Buy |
+74,858
| New | +$1.29M | ﹤0.01% | 3548 |
|
Other funds holding ACIU
BI
DIG
Ken Griffin's ACIU Position: Q1 2026 in Review
Ken Griffin increased its AC Immune (ACIU) stake by 276% in Q1 2026, buying an estimated $609K and bringing the position to 267,233 shares worth $735K. The position accounts for ﹤0.01% of the portfolio, ranked #8401.
Ken Griffin first reported a position in ACIU in Q3 2016 and has held it in 31 quarters since. The position peaked at $4.85M in Q4 2016. 46 funds tracked by Wall St. Rank hold ACIU as of Q1 2026.
- Ken Griffin held 267,233 shares of AC Immune worth $735K as of Q1 2026.
- Ken Griffin bought 196,082 AC Immune shares in Q1 2026, an estimated $609K.
- AC Immune made up ﹤0.01% of Ken Griffin's portfolio in Q1 2026, its #8401 holding.
- Ken Griffin first reported a position in AC Immune in Q3 2016 and has held it in 31 quarters since.
- Ken Griffin's AC Immune position peaked at $4.85M in Q4 2016.
- 46 funds tracked by Wall St. Rank held AC Immune as of Q1 2026.
Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.